MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

39.78 +1.20 (+3.11%)
Official Closing Price Updated: 7:00 PM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 23,796,022
Open 39.19
Bid (Size) 39.60 (200)
Ask (Size) 39.80 (100)
Prev. Close 38.58
Today's Range 38.49 - 39.88
52wk Range 35.85 - 82.57
Shares Outstanding N/A
Dividend Yield 2.94%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
HIMS Stock Rockets To Best Day Ever After Novo Nordisk Pact — Wall Street Upgrades Roll In As Shorts Lose $546M In One Day ↗
Short interest totalled about $1.39 billion, or roughly 42.83% of the float, according to S3 Partners. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy? ↗
Hims & Hers stock traded more than 40% higher after the deal was announced. 
Via The Motley Fool
Topics Lawsuit

Performance

YTD
-24.1%
-24.1%
1 Month
-19.4%
-19.4%
3 Month
-14.9%
-14.9%
6 Month
-26.7%
-26.7%
1 Year
-49.6%
-49.6%

More News

Read More
News headline image
Novo Nordisk Is Slashing Prices for Ozempic and Wegovy. Here's Why That Might End Up Helping the Stock ↗
Via The Motley Fool
News headline image
Hims & Hers Stock Pops 40%: Everything You Need to Know ↗
Via The Motley Fool
Topics Lawsuit
News headline image
HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy ↗
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
HIMS Stock Could Rally Up To 60% This Week? Fund Manager Says He Wouldn’t Be ‘Surprised’ As Novo Nordisk Patch-Up Buzz Grows ↗
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
Better Weight Loss Stock: Novo Nordisk Vs. Amgen ↗
Via The Motley Fool
News headline image
2 Underrated Weight Loss Stocks to Buy Now ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Can This Next-Gen Obesity Drug Save Novo Nordisk? ↗
Via The Motley Fool
News headline image
Novo Nordisk To Partner With Hims & Hers To Sell Weight-Loss Drugs: Report ↗
Via Stocktwits
Topics Initial Public Offering Intellectual Property Lawsuit
News headline image
Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market? ↗
Via The Motley Fool
News headline image
Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors ↗
Via The Motley Fool
News headline image
The Compounding Cliff: Hims & Hers Faces Reckoning as FDA and Big Pharma Close GLP-1 Loopholes
Via MarketMinute
Topics Economy Intellectual Property Lawsuit
News headline image
Novo Nordisk’s Brief Rebound Fizzles: Apple-Style Justin Long Ozempic Ad Draws FDA Warning Again ↗
Via Stocktwits
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Unexpected Stock Picks and Looking to the Future ↗
Via The Motley Fool
News headline image
Why I'm Not Worried About Novo Nordisk Stock ↗
Via The Motley Fool
Topics Intellectual Property
MarketBeat Week in Review – 02/23 - 02/27 ↗
Via MarketBeat
News headline image
The Great Divergence: AI Supremacy Masks a Hidden Bear Market in Healthcare and Industrials
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan
Via MarketMinute
Topics Artificial Intelligence ETFs
News headline image
The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026
Via Finterra
Topics Economy Intellectual Property
News headline image
Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making ↗
Via The Motley Fool
News headline image
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗
Via The Motley Fool
News headline image
Why Shares of Novo Nordisk Stock Sank (Again) This Week ↗
Via The Motley Fool

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 39.78
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 03/09/26 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story